Naomi J. P. Thomas

Naomi J. P. Thomas

Auto-generated profile, based on publicly available information

Naomi J. P. Thomas

Wellcome Centre for Mitochondrial Research, Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2020 in The Lancet Psychiatry
Verified
Journal Article
Closed access
AVAravinthan Varatharaj
Aravinthan Varatharaj
NTNaomi Thomas
Naomi Thomas
MEMark A Ellul
Mark A Ellul
NDNicholas W S Davies
Nicholas W S Davies
TPThomas A Pollak
Thomas A Pollak
GPGordon Plant
Gordon Plant

5 June 2020 in Journal of Neurology, Neurosurgery & Psychiatry
Verified
Journal Article
Open access
PDF file
MEMark Ellul
Mark Ellul
AVAravinthan Varatharaj
Aravinthan Varatharaj
TNTimothy R Nicholson
Timothy R Nicholson
TPThomas Arthur Pollak
Thomas Arthur Pollak
NTNaomi Thomas
Naomi Thomas
BMBenedict D. Michael
Benedict D. Michael

20 September 2022 in Trials
Verified
Journal Article
Open access
PDF file
AAAlaa Abouhajar
Alaa Abouhajar
LALisa Alcock
Lisa Alcock
TBTheophile Bigirumurame
Theophile Bigirumurame
PBPenny Bradley
Penny Bradley
LBLaura Brown
Laura Brown
GWGillian Watson
Gillian Watson
Background: Mitochondrial disease is a heterogenous group of rare, complex neurometabolic disorders. Despite their individual rarity, collectively mitochondrial diseases represent the most common cause of inherited metabolic disorders in the UK; they affect 1 in every 4300 individuals, up to 15,000 adults (and a similar number of children) in the UK. Mitochondrial disease manifests multisystem and isolated organ involvement, commonly affecting those tissues with high energy demands, such as skeletal muscle. Myopathy manifesting as fatigue, muscle weakness and exercise intolerance is common and debilitating in patients with mitochondrial disease. Currently, there are no effective licensed treatments and consequently, there is an urgent clinical need to find an effective drug therapy. Aim: To investigate the efficacy of 12-week treatment with acipimox on the adenosine triphosphate (ATP) content of skeletal muscle in patients with mitochondrial disease and myopathy. Methods: AIMM is a single-centre, double blind, placebo-controlled, adaptive designed trial, evaluating the efficacy of 12 weeks’ administration of acipimox on skeletal muscle ATP content in patients with mitochondrial myopathy. Eligible patients will receive the trial investigational medicinal product (IMP), either acipimox or matched placebo. Participants will also be prescribed low dose aspirin as a non-investigational medical product (nIMP) in order to protect the blinding of the treatment assignment. Eighty to 120 participants will be recruited as required, with an interim analysis for sample size re-estimation and futility assessment being undertaken once the primary outcome for 50 participants has been obtained. Randomisation will be on a 1:1 basis, stratified by Fatigue Impact Scale (FIS) (dichotomised as < 40, ≥ 40). Participants will take part in the trial for up to 20 weeks, from screening visits through to follow-up at 16 weeks post randomisation. The primary outcome of change in ATP content in skeletal muscle and secondary outcomes relating to quality of life, perceived fatigue, disease burden, limb function, balance and walking, skeletal muscle analysis and symptom-limited cardiopulmonary fitness (optional) will be assessed between baseline and 12 weeks. Discussion: The AIMM trial will investigate the effect of acipimox on modulating muscle ATP content and whether it can be repurposed as a new treatment for mitochondrial disease with myopathy. Trial registration: EudraCT2018-002721-29. Registered on 24 December 2018, ISRCTN 12895613. Registered on 03 January 2019, https://www.isrctn.com/search?q=aimm

1 September 2007 in British Journal of Diabetes
Verified
Journal Article
Closed access
PDF file
NTNaomi Thomas
Naomi Thomas
JSJohn Scanlon
John Scanlon
MAMunir Ahmed
Munir Ahmed

7 December 2006 in BMJ
Verified
Journal Article
Closed access
PDF file
RTRhys H Thomas
Rhys H Thomas
NTNaomi J P Thomas
Naomi J P Thomas
Footnotes Competing interests: RHT was hoping to make his fortune from the hiccough cure. NJPT frequently benefits from the miracle cure.

4 April 2019 in Practical Neurology
Verified
Journal Article
Closed access
PDF file
RTRhys H Thomas
Rhys H Thomas
NTNaomi J P Thomas
Naomi J P Thomas